Alnylam, Sanofi Restructure RNAi Rare-Disease Alliance
January 07 2018 - 3:59PM
Dow Jones News
By Colin Kellaher
Alnylam Pharmaceuticals Inc. (ALNY) and Sanofi (SNY) on Sunday
said they agreed to restructure their RNAi therapeutics alliance to
streamline and optimize development of certain products for the
treatment of rare genetic diseases.
As part of the restructuring, Cambridge, Mass.,
biopharmaceutical company Alnylam will obtain global development
and commercialization rights to its investigational RNAi
therapeutics programs for the treatment of ATTR amyloidosis,
including patisiran and ALN-TTRsc02, while Sanofi obtains global
development and commercialization rights to fitusiran, an
investigational therapeutic in development for the treatment of
hemophilia A and B.
France's Sanofi will receive royalties based on net sales of the
ATTR amyloidosis products, and Alnylam will receive royalties based
on sales of fitusiran products.
The companies said terms of their 2014 agreement with respect to
other products under the alliance are unchanged.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 07, 2018 15:44 ET (20:44 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Sep 2023 to Sep 2024